Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report)'s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $14.18, but opened at $14.93. Pharming Group shares last traded at $14.86, with a volume of 2,347 shares changing hands.
Pharming Group Price Performance
The firm has a market capitalization of $1.01 billion, a P/E ratio of -113.51 and a beta of 0.05. The firm has a 50 day moving average price of $13.02 and a 200-day moving average price of $10.84. The company has a current ratio of 2.79, a quick ratio of 2.07 and a debt-to-equity ratio of 0.38.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.16. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. The firm had revenue of $93.20 million during the quarter, compared to analyst estimates of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. On average, analysts expect that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC acquired a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,979 shares of the company's stock, valued at approximately $32,000. Hedge funds and other institutional investors own 0.03% of the company's stock.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
